Ginkgo Bioworks Holdings, Inc.’s DNA share price has surged by 14.49%, which has investors questioning if this is right time ...

BOSTON—Steven P. Coen, the Chief Accounting Officer at Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), recently sold shares of the company's Class A Common Stock valued at approximately $4,933. The ...

Boston, MA – Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) recently reported a stock transaction by its Chief Financial Officer, Mark E. Dmytruk, according to a recent SEC filing. The transaction comes as ...

Ginkgo Bioworks Holdings, Inc.’s DNA share price has dipped by 16.38%, which has investors questioning if this is right time to buy.

Ginkgo Bioworks Holdings Inc, based in Boston, Massachusetts, specializes in cell programming to revolutionize the production of various products. By manipulating cells, they create novel ...

Therefore, the Zacks rating upgrade for Ginkgo Bioworks basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

TD Cowen analyst Brendan Smith raised the firm’s price target on Ginkgo Bioworks (DNA) to $16 from $10 and keeps a Buy rating on the shares.

北京时间2025年01月17日01时55分，Ginkgo Bioworks Holdings, Inc.（DNA.us）股票出现波动，股价快速上涨5.00%。截至发稿，该股报9.77美元 ...